Related Experiment Videos
[Silent ischemia. To treat or not to treat?]
J López-Sendón1, F Ramos, I Gonzalez Maqueda
1Servicio Coronariopatias, Hospital La Paz, Madrid.
Insights
Silent myocardial ischemia, characterized by transient heart muscle damage without chest pain, is increasingly significant in higher-risk patients. Identifying and treating this condition aims to improve patient prognosis.
Area of Science:
- Cardiology
- Internal Medicine
Context:
- Silent myocardial ischemia presents without typical angina, encompassing metabolic, functional, electrocardiographic, and anatomic abnormalities.
- Its prevalence, prognostic implications, and treatment necessity vary significantly across different patient demographics.
Purpose:
- To review the current understanding of silent myocardial ischemia, including its identification and clinical significance.
- To differentiate patient groups based on risk and discuss treatment strategies.
Summary:
- The incidence and prognostic significance of silent myocardial ischemia generally increase from low-risk to high-risk patient groups.
- Key patient categories include normal subjects, those with stable coronary heart disease, and those with unstable heart disease.
- While anti-ischemic drugs and revascularization can reduce the occurrence and severity of silent ischemia, their impact on overall prognosis remains under investigation.
Impact:
- This review highlights the importance of recognizing silent myocardial ischemia, particularly in high-risk populations.
- It emphasizes that the primary goal of managing silent ischemia is to improve long-term patient prognosis.
- Understanding these concepts is crucial for refining diagnostic and therapeutic approaches in cardiovascular medicine.
Abstract:
Silent myocardial ischaemia can be defined as the presence of transient ischaemic alterations in absence of angina. Those include metabolic, functional, electrocardiographic and anatomic abnormalities without typical chest pain. Its incidence, prognostic significance, possible identification in clinical practice as well as need for treatment varies according to the group of patients. In the present review, we discuss these concepts in base of the knowledge supported by the results of different studies. As a rule, the incidence, prognostic significance, and henceforth the need for its identification, increase from the low risk groups of patients to those of high risk according to classical criteria. To this respect, it is useful to differentiate three groups of patients: normal subjects, stable coronary heart disease and unstable heart disease. Medical treatment with anti-ischaemic drugs as well as myocardium revascularization procedures have shown to decrease the incidence and severity of silent myocardial ischaemia, but its influence on prognosis is unknown, and it should be emphasized that the main objective in the treatment of silent ischaemia is improve prognosis.